{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"6"}],"units":"Participants"}],"description":"Treatment-emergent Adverse Events (TEAEs) in participants regardless of causality while taking PLX3397 in combination with pembrolizumab are reported","groups":[{"description":"Participants received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 400 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 200 mg in the evening).","id":"OG000","title":"Dose Escalation: 400 mg/Day"},{"description":"Participants received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG001","title":"Dose Escalation: 600 mg/Day"},{"description":"Participants with liver metastases received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG002","title":"Dose Escalation: 600 mg/Day (Liver Metastases"},{"description":"Participants with no liver metastases received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG003","title":"Dose Escalation: 600 mg/Day (no Liver Metastases)"},{"description":"Participants with liver metastases received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 800 mg/day (administered twice daily \\[BID\\] as a split dose of 400 mg in the morning and 400 mg in the evening).","id":"OG004","title":"Dose Escalation: 800 mg/Day (Liver Metastases)"},{"description":"Participants with no liver metastases received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 800 mg/day (administered twice daily \\[BID\\] as a split dose of 400 mg in the morning and 400 mg in the evening).","id":"OG005","title":"Dose Escalation: 800 mg/Day (no Liver Metastases)"},{"description":"Participants with melanoma received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG006","title":"Dose Expansion: Melanoma"},{"description":"Participants with NSCLC received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG007","title":"Dose Expansion: NSCLC"},{"description":"Participants with ovarian cancer received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG008","title":"Dose Expansion: Ovarian Cancer"},{"description":"Participants with SCCHN received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG009","title":"Dose Expansion: SCCHN"},{"description":"Participants with GIST received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG010","title":"Dose Expansion: GIST"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety events were assessed in the Safety Population.","reportingStatus":"POSTED","timeFrame":"1 year (Dose Escalation); 2 years (Dose Expansion)","title":"Treatment-emergent Adverse Events (TEAEs) in Participants Regardless of Causality While Taking PLX3397 in Combination With Pembrolizumab","type":"PRIMARY","unitOfMeasure":"Participants"}